Looking for a specific product?

Make a search for products & suppliers, articles & news.

Bionor Pharma's First Reboost Vacc-4x Study Accepted for Publication in the Vaccine Journal

Bionor Pharma ASA (OSE: BIONOR) announces that the results from the Company’s first re-boost clinical trial of Vacc-4x have been accepted for publication in the renowned journal Vaccine. 

The Phase II trial was conducted at Oslo University Hospital and completed in 2010. The trial investigated the effect of re-boosting 22 available patients from previous study with the Company’s leading therapeutic HIV vaccine candidate Vacc-4x.  The study demonstrated that it is possible to elicit strong memory immune responses up to 7 years after the initial vaccination. 

 

 

If you would like to read more, visit Bionor Pharam's website here.

Associated companies:


Related news

Latest news

Eimskip strengthens its worldwide forwarding services by acquiring the logistics company SHIP-LOG A/S in Denmark

Eimskip has strengthened its position in worldwide logistics services by acquiring 75% of the freight forwarding company SHIP-LOG. 

For Sale Assets from the former BMV LAKSEVÄG YARD in Bergen, Norway!

For Sale Assets from the former BMV LAKSEVÄG YARD in Bergen, Norway! The entire shipbuilding and fabricating facility is closing and more than 500 lots is on sale.

Servogear CPP for Seasight II - Future of the Fjords

We are proud to announce that Servogear has been chosen for the delivery of Servogear...

TechnipFMC Signs Agreement with Pall to Supply Slurry Oil Filtration Systems for Fluid Catalytic Cracking Units

The associated activities will be managed by TechnipFMC Process Technology’s center in Houston,

10 Million kroner for verification funding

The Norwegian Research Council has granted 10 million...

Hilti acquires Oglaend System Group

Oglaend System’s headquarters will remain in Klepp, 

DOF Subsea AS ("DOF Subsea" or the "Company") today announces its intention to launch an initial public offering (the "IPO") of its ordinary shares and to apply for a listing on Oslo Børs

NOT FOR DISTRIBUTION OR RELEASE,

DOF Subsea North America extends charter for Jones Act Compliant vessel Harvey Deep Sea

The Harvey Deep Sea Vessel is a Multi-Purpose DPII Construction,

Untrue rumours about an on-going incident at the Halden Research Reactor in Norway

The Norwegian Radiation Protection Authority has become aware that stories about an ongoing incident involving a “meltdown” at the Norwegian Institute for Energy Technology (IFE) reactor situated in Halden are currently ci...